Remifentanil Hydrochloride

CAS 132875-61-7 11 current recordsSmall Molecule

Who holds supplier records for Remifentanil Hydrochloride? 11 organisations hold a current record for Remifentanil Hydrochloride: an active US FDA Type II Drug Master File or a CEP. 8 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: United States (2), Switzerland (1), South Africa (1), China (1) and 5 other countries (5); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Remifentanil Hydrochloride: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/remifentanil-hydrochloride

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Remifentanil Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Remifentanil Hydrochloride sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (8)

Certificates of Suitability on the EDQM register for Remifentanil Hydrochloride, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 9 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
MINAKEM HIGH POTENT Mont-Saint-GuibertBE
CEP 2020-323 - Rev 01
Remifentanil hydrochloride
Sept 2026—
HAMELN RDS S.R.O. ModraSK
CEP 2018-125 - Rev 05
Remifentanil hydrochloride
Apr 2026Inspected Mar 2026
Slovakia
CILAG AG SchaffhausenCH
CEP 2018-296 - Rev 02
Remifentanil hydrochloride
Feb 2025Inspected Nov 2025
Switzerland
MACFARLAN SMITH LIMITED EdinburghGB
CEP 2018-137 - Rev 01
Remifentanil hydrochloride
Aug 2024—
FINE CHEMICALS CORPORATION (PTY) LTD. GoodwoodZA
CEP 2018-240 - Rev 03
Remifentanil hydrochloride
Jun 2024Inspected Jul 2024
Germany
AREVIPHARMA GMBH RadebeulDE
CEP 2018-070 - Rev 01
Remifentanil hydrochloride
Feb 2024Inspected Jun 2025
Germany
YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. YichangCN
CEP 2018-193 - Rev 01
Remifentanil hydrochloride
Oct 2023Inspected Jul 2026
Hungary
Kern Pharma, S.L. TerrassaES
R1-CEP 2017-065 - Rev 00
Remifentanil hydrochloride
Jan 2023—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Remifentanil Hydrochloride is a potent, short-acting synthetic opioid analgesic used in general anesthesia. It acts directly on opioid receptors to produce pain relief with rapid onset and termination of action.

Chemical identity

IUPAC name
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate;hydrochloride
Canonical SMILES
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC.Cl
InChIKey
WFBMIPUMYUHANP-UHFFFAOYSA-N
Synonyms
Ultiva API, gi 87084b, gi-87084b, remifentanil hcl, ultiva

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Opioid Agonist
Mechanism of action
Full Opioid Agonists

Therapeutic areas

Anesthesia

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Remifentanil Hydrochloride?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Remifentanil Hydrochloride: CILAG AG (Switzerland), Fine Chemicals Corporation (PTY) Ltd. (South Africa), YICHANG HUMANWELL PHARMACEUTICAL CO LTD (China), Ampac Fine Chemicals (United States), NAVINTA LLC (United States), VERANOVA LP (United Kingdom), Arevipharma GmbH (Germany) and hameln rds s.r.o. (Slovakia), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Remifentanil Hydrochloride Drug Master Files are active?

CILAG AG (DMF 27513), Fine Chemicals Corporation (PTY) Ltd. (DMF 28106), YICHANG HUMANWELL PHARMACEUTICAL CO LTD (DMF 33151), Ampac Fine Chemicals (DMF 34303), NAVINTA LLC (DMF 30156) and VERANOVA LP (DMF 25811). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does Remifentanil Hydrochloride have a European Certificate of Suitability?

Yes. 8 organisations hold a valid CEP for Remifentanil Hydrochloride on the EDQM register, including MINAKEM HIGH POTENT Mont-Saint-Guibert (BE), HAMELN RDS S.R.O. Modra (SK), CILAG AG Schaffhausen (CH), MACFARLAN SMITH LIMITED Edinburgh (GB), FINE CHEMICALS CORPORATION (PTY) LTD. Goodwood (ZA) and AREVIPHARMA GMBH Radebeul (DE) and 2 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Remifentanil Hydrochloride supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Remifentanil Hydrochloride?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.